10-Q: Akoya Biosciences Reports Q1 2025 Results Amidst Merger Agreement with Quanterix

Akoya Biosciences announces its Q1 2025 financial results, showing a net loss but also highlighting its ongoing merger agreement with Quanterix.

Summary

• Akoya Biosciences reported a net loss of $15.7 million for the three months ended March 31, 2025, compared to a net loss of $23.5 million for the same period in 2024.
• Total revenue decreased by 9% to $16.6 million, with product revenue slightly down and service and other revenue significantly lower.
• The company's gross profit increased to $9.9 million, with a gross margin of 59%, compared to $8.4 million and 46% respectively in the prior year.
• Operating expenses decreased due to workforce reductions and exiting a facility, but were offset by merger-related professional fees.
• The company had $27.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
• Akoya is currently in a merger agreement with Quanterix, which is expected to close in the second quarter of 2025.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months if the merger is not consummated.
• The company was not in compliance with certain covenants under the Midcap Trust Term Loan as of March 31, 2025, but is in compliance after giving effect to Amendment No. 6.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company improved its net loss and gross margin, revenue declined, and there are concerns about its ability to continue as a going concern if the merger is not completed. The merger itself introduces uncertainty.

Positives

• Net loss decreased from $23.5 million to $15.7 million year-over-year.
• Gross margin increased from 46% to 59% year-over-year.
• Operating expenses decreased by 22% due to cost-saving initiatives.
• The company is in compliance with all covenants under the Midcap Trust Term Loan as of March 31, 2025 and through the date these consolidated financial statements were issued, after giving effect to Amendment No. 6.

Negatives

• Total revenue decreased by 9% year-over-year.
• Service and other revenue decreased by 26% year-over-year.
• The company has an accumulated deficit of $301.1 million as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months if the merger is not consummated.

Risks

• The merger with Quanterix is subject to customary closing conditions and may not be completed.
• Failure to maintain compliance with financial covenants under the Midcap Trust Term Loan could lead to default and lender remedies.
• The company's future capital requirements depend on successful commercialization and product launches.
• The company may not be able to raise additional financing on acceptable terms or at all.
• Changes in US trade policies, including the imposition of tariffs, may adversely impact the business, financial condition, and results of operations.
• There is substantial uncertainty regarding the new administrations initiatives and how these might impact the FDA, its implementation of laws, regulations, policies and guidance and its personnel.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future but plans to focus on improving results of operations in an effort to achieve cash flow positivity.

Industry Context

Akoya Biosciences operates in the rapidly evolving spatial biology solutions market, competing with companies offering technologies for tissue analysis and spatial phenotyping. The merger with Quanterix aims to create a stronger entity in the diagnostics and life sciences research space.

Comparison to Industry Standards

• It is difficult to compare Akoya's results directly to industry standards without specific benchmarks for spatial biology companies.
• Comparable companies in the life sciences tools and diagnostics sector include NanoString Technologies, Bio-Techne, and Agilent Technologies.
• These companies typically have higher revenue and are profitable, but they also operate in more mature markets.
• Akoya's gross margin of 59% is within the range of other life science companies, but its net loss indicates it is still in a growth phase.
• The merger with Quanterix is likely aimed at achieving greater scale and profitability, similar to other consolidation trends in the industry.

Related Party Transactions

• The Company incurred costs of goods sold of approximately $0 related to sales of consumables manufactured by and shipped from AMS.
• The Company incurred research and development expenses of approximately $127 with AMS.
• The Company incurred research and development expenses of $295 with a software-as-a-service provider.

Stakeholder Impact

• Shareholders face uncertainty regarding the value of the merger consideration and the future performance of the combined company.
• Employees may experience changes due to the merger or potential restructuring if the merger is not completed.
• Customers may benefit from the combined product offerings and services of Akoya and Quanterix.
• Suppliers and creditors face potential changes in relationships depending on the outcome of the merger and the company's financial stability.

Next Steps

• Complete the merger with Quanterix, expected in Q2 2025.
• Seek a waiver or refinance the Midcap Trust Term Loan if the merger is not consummated.
• Focus on improving results of operations to achieve cash flow positivity.
• Continue to commercialize and launch products to increase revenue.

Key Dates

Keywords

Akoya Biosciences, Quanterix, Merger, Financial Results, Spatial Biology, Q1 2025, Revenue, Net Loss, Midcap Trust Term Loan, Going Concern